Our ultramodern multi-purpose drug product site in Chile contains highly advanced facilities varying from development to large-scale production of tablets and capsules. The plant has been GMP approved by both the Chilean and European health authorities and complements our Barcelona drug product facility in serving global markets in terms of production as well as R&D.
The site is highly sustainable and the first drug product manufacturing plant in Chile to obtain approval by an EU health authority to manufacture products for the EU market. With its 350 employees, the site handles over 50 different products (molecules/strengths) from both the local and Synthon's global portfolio.go to Synthon Chile website
Conventional drug products capacity